Alpine Immune Sciences, Inc.
NASDAQ:ALPN
64.97 (USD) • At close May 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 58.876 | 30.064 | 23.443 | 9.335 | 1.74 | 0.705 | 1.731 | 2.95 | 0.492 | 0 | 0 | 0 |
| Cost of Revenue
| 0.576 | 0.597 | 0.62 | 27.185 | 35.847 | 28.97 | 10.626 | 0.143 | 0.066 | 0 | 0 | 0 |
| Gross Profit
| 58.3 | 29.467 | 22.823 | -17.85 | -34.107 | -28.265 | -8.895 | 2.807 | 0.426 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.99 | 0.98 | 0.974 | -1.912 | -19.602 | -40.092 | -5.139 | 0.952 | 0.866 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 80.328 | 70.243 | 58.742 | 27.185 | 35.847 | 28.97 | 10.626 | 23.316 | 16.054 | 12.2 | 13.136 | 7.1 |
| General & Administrative Expenses
| 22.222 | 17.968 | 14.56 | 10.899 | 9.467 | 8.362 | 6.079 | 8.586 | 6.844 | 2.288 | 2.141 | 1.929 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 22.222 | 17.968 | 14.56 | 10.899 | 9.467 | 8.362 | 6.079 | 8.586 | 6.844 | 2.288 | 2.141 | 1.929 |
| Other Expenses
| 0.415 | -0.097 | -0.004 | 1.333 | 0.812 | 1.203 | 0 | 0 | 0.08 | 0.296 | 0 | 0.151 |
| Operating Expenses
| 102.55 | 88.211 | 73.302 | 38.084 | 45.314 | 37.332 | 16.705 | 31.902 | 22.898 | 14.487 | 15.277 | 9.03 |
| Operating Income
| -44.25 | -58.147 | -49.859 | -28.749 | -43.574 | -37.83 | -14.974 | -31.902 | -22.898 | -14.487 | -15.277 | -9.03 |
| Operating Income Ratio
| -0.752 | -1.934 | -2.127 | -3.08 | -25.043 | -53.66 | -8.65 | -10.814 | -46.541 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 12.169 | 2.715 | -0.561 | 0.803 | 1.722 | -1.203 | 6.601 | 0.439 | 0.08 | 0.296 | 0.01 | 0.151 |
| Income Before Tax
| -32.081 | -55.432 | -50.42 | -27.946 | -41.852 | -36.853 | -7.983 | -31.463 | -22.818 | -15.036 | -16.198 | -9.573 |
| Income Before Tax Ratio
| -0.545 | -1.844 | -2.151 | -2.994 | -24.053 | -52.274 | -4.612 | -10.665 | -46.378 | 0 | 0 | 0 |
| Income Tax Expense
| 0.103 | 2.33 | -0.087 | -0.006 | 0.682 | -0.366 | -0.2 | -0.143 | -0.066 | 1.141 | 0.941 | 0.845 |
| Net Income
| -32.184 | -57.762 | -50.333 | -27.94 | -42.534 | -36.487 | -7.783 | -31.463 | -22.818 | -15.036 | -16.198 | -9.573 |
| Net Income Ratio
| -0.547 | -1.921 | -2.147 | -2.993 | -24.445 | -51.755 | -4.496 | -10.665 | -46.378 | 0 | 0 | 0 |
| EPS
| -0.64 | -1.73 | -1.98 | -1.34 | -2.32 | -2.63 | -1.2 | -8.12 | -9.74 | -6.59 | -7.1 | -4.2 |
| EPS Diluted
| -0.64 | -1.73 | -1.98 | -1.34 | -2.32 | -2.63 | -1.2 | -8.12 | -9.74 | -6.59 | -7.1 | -4.2 |
| EBITDA
| -43.674 | -54.956 | -49.604 | -27.171 | -41.514 | -35.331 | -14.191 | -31.902 | -22.898 | -14.104 | -15.048 | -8.667 |
| EBITDA Ratio
| -0.742 | -1.828 | -2.116 | -2.911 | -23.859 | -50.115 | -8.198 | -10.814 | -46.541 | 0 | 0 | 0 |